Cancer patients enrolled in Humana Medicare Advantage plans who receive treatment at Moffitt Cancer Center in Tampa face a forced choice this month: switch to a different insurance plan or absorb out-of-network costs for their ongoing care. The network exit strips in-network access to one of the nation’s top cancer treatment facilities for an undisclosed number of Medicare Advantage enrollees, compressing their decision window into weeks rather than months. Federal rules require standardized notices spelling out appeal and grievance rights, but the speed of the disruption raises questions about whether patients can act before their coverage terms change.
Why Moffitt’s exit from Humana’s network puts patients in a bind
When a major cancer center drops out of a Medicare Advantage network, the consequences land hardest on patients mid-treatment. Switching oncologists or facilities during chemotherapy, radiation, or immunotherapy cycles can delay care, disrupt clinical trial enrollment, and introduce new providers unfamiliar with a patient’s history. For enrollees who stay with Humana, continuing at Moffitt means paying out-of-network rates, which in cancer care can run tens of thousands of dollars per treatment cycle.
The central question for affected patients is whether they received notice early enough to file grievances, request continuity-of-care exceptions, or switch plans before the change takes effect. CMS requires Medicare Advantage plans to issue standardized notices that explain grievance procedures, coverage determinations, and appeal rights when network access changes. Patients who receive those notices with adequate lead time have a realistic path to challenge the disruption or secure alternative coverage. Those who learn about the exit late face a much narrower set of options.
The hypothesis that early notice drives higher grievance and appeal filing rates has a practical logic: patients who know their rights and deadlines are more likely to use them. But the absence of public data on how many Humana enrollees at Moffitt received timely notification, or how many have already filed complaints, makes it impossible to measure that effect in this case. For now, patient advocates are left to infer likely impacts from the structure of federal rules and the lived experience of people trying to navigate a complex benefits system while seriously ill.
Federal notice rules and the regulatory framework behind network changes
Federal regulation sets the floor for how Medicare Advantage plans must handle disruptions. The regulatory text at 42 CFR 422.510, which governs termination of Medicare Advantage contracts by CMS, includes explicit enrollee notification timing requirements. While that provision addresses plan-level contract terminations rather than individual provider-network exits, it establishes the principle that beneficiaries deserve advance warning and clear instructions when their coverage changes.
CMS maintains a library of standardized notice templates covering grievances, organization determinations, appeals, and hospital discharge rights. These forms are designed to give enrollees a consistent, readable explanation of what they can do when their plan’s network shifts. Enrollees who need help sorting through their options can access free counseling through CMS-affiliated assisters or review qualifying coverage definitions to understand what alternative plans might accept them.
The gap between what the rules require and what patients experience in practice is where the real friction sits. A standardized letter arriving in a mailbox does not guarantee that a patient undergoing active cancer treatment has the time, energy, or resources to compare plans, file an appeal, and secure uninterrupted care before a deadline passes. Patients who also qualify for programs administered through Medicaid coverage may have additional options, but coordinating benefits across multiple payers is notoriously difficult, especially for older adults juggling complex treatment regimens.
What patients can do when a cancer center goes out of network
For patients caught in the middle of a network change, the immediate priority is clarifying timelines. The effective date of Moffitt’s exit from Humana’s network determines how long current in-network rates apply and when higher out-of-network cost sharing would begin. Plan documents and any mailed notices should specify that date, along with instructions for filing grievances or requesting exceptions.
In some circumstances, Medicare Advantage enrollees may qualify for a special enrollment period that allows them to switch plans outside the normal annual window. Whether a particular network change triggers that right depends on CMS rules and the specifics of the disruption. Patients who believe they qualify can contact 1‑800‑MEDICARE or local counseling programs to confirm their options and deadlines.
Another potential avenue is continuity-of-care or transition-of-care requests. Some plans will temporarily honor in-network cost sharing for ongoing treatment at an out-of-network provider, especially for complex or life-threatening conditions. These arrangements are not guaranteed and often require proactive outreach, documentation from treating physicians, and persistence in following up with the plan.
Low-income patients and those dually eligible for Medicare and Medicaid have an additional layer of potential support. State Medicaid agencies and related programs sometimes offer case management, transportation assistance, or help with premiums and cost sharing. The federal site’s directory of state-level resources can connect beneficiaries with local offices that explain how Medicaid and Medicare Advantage interact in their jurisdiction.
The broader policy questions raised by the Humana–Moffitt split
Beyond the immediate scramble for affected patients, Moffitt’s departure from Humana’s network highlights a structural tension in Medicare Advantage. Insurers use narrow networks to control costs, while patients value stable relationships with trusted specialists, especially in oncology. When contract negotiations break down, the formal safeguards-advance notice, grievance rights, and appeal processes-may not be enough to prevent care disruptions.
Policymakers and regulators face pressure to determine whether current notice requirements and special enrollment rules adequately protect beneficiaries when high-profile cancer centers leave plan networks. The Humana–Moffitt split will likely feed into ongoing debates over how much leverage plans should have in network design and how much risk patients should bear when those networks change midstream.
For now, the practical reality in Tampa is stark: cancer patients who built their care plans around Moffitt must navigate a compressed timeline, dense paperwork, and uncertain financial exposure. The formal rights embedded in federal regulations matter, but their value ultimately depends on whether patients can exercise them in time.
Free for readers: The free Retirement Shield newsletter sends plain-English help keeping more of your money in retirement — the scams to dodge, the benefits you’re owed, and what’s changing with Social Security and Medicare, a couple times a week. Get the free newsletter.
